A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.
Also called NCT05425056
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 136 participants
- Sponsor
- Vascular Therapies, Inc.
- Registry
-
NCT05425056
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05425056. Randomized; triple masking; primary purpose prevention. Start 2022-08-26 (actual); primary completion 2025-03-18 (actual). Results posted on 2026-10-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
- Acronym
- ACCESS2
- Condition
- Complication of Renal Dialysis
- Condition
- End Stage Renal Disease
- Condition
- End Stage Kidney Disease
- Condition
- ESRD
- Condition
- Chronic Kidney Failure
- Condition
- Complication of Hemodialysis
- Condition
- Vascular Access Complication
- Condition
- Arteriovenous Fistula
- Intervention (Drug)
- Sirolimus
- Lead sponsor
- Vascular Therapies, Inc.
Record details
- Record id
cardio:ct-nct05425056- Content hash
0fdc90a4b92bed070b457b4e8c85148c9e5d10d81d128cf0d75cc6172f65cdba